Immuron Limited ADR (IMRN) — Titan Protect Analysis

IMRN

Immuron Limited ADR

Healthcare · ·

$1.25

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$11M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-134.00

Based on estimated future earnings — lower means cheaper

Rev Growth

+4.8%

Year-over-year revenue change

Profit Margin

-62.1%

How much profit the company keeps from each dollar of revenue

ROE

-39.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$3.99

+219% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Immuron Limited ADR

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune su

https://www.immuron.com.au

Country: Australia Employees: 7 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.009

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0547

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.355

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-26.6%

Historical annualised return based on price data

Max Drawdown

-75.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.41

Very low correlation to market moves

52W High

$2.39

48% below the year high

52W Low

$0.68

85% above the year low

Avg Volume

232,096

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.54

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.56

Meaningful debt load — monitor closely

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

63.7%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-47.2%

Profit from core operations before interest and tax

Free Cash Flow

$-3,420,940

Negative — the business is spending more than it generates

Revenue (TTM)

$7M

Total revenue over the last 12 months

Net Income

$-4,646,242

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$3.99

Target Median

$3.99

Target Low

$3.99

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go